Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.42 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.42 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25346919 | 0.98 | CYP3A4 (0.48) | CYP3A4TPSAB1TPSD1TPSG1IDO1 | |
| SCHEMBL18705411 | 0.97 | CYP3A4 (0.43) | CYP3A4TPSAB1TPSD1TPSG1IDO1 | |
| SCHEMBL22946820 | 0.94 | HPGD (0.41) | CYP3A4IDO1HDAC3HDAC4HDAC1 | |
| SCHEMBL22021517 | 0.93 | EPHX2 (0.41) | CYP3A4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL10177563 | 0.89 | HTT (0.47) | CYP3A4IDO1HDAC3HDAC4HDAC1 | |
| SCHEMBL29959208 | 0.88 | HTT (0.49) | CYP3A4IDO1HDAC3HDAC4HDAC1 | |
| SCHEMBL18879474 | 0.88 | MAPT (0.48) | CYP3A4IDO1HDAC3HDAC4HDAC1 | |
| SCHEMBL25752594 | 0.88 | HPGD (0.48) | CYP3A4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL27250873 | 0.87 | HDAC8 (0.41) | HDAC8MAPTL3MBTL1SYKEPHX2 | |
| SCHEMBL17599919 | 0.87 | CYP3A4 (0.59) | CYP3A4TPSAB1TPSD1TPSG1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240175018-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-05-30 | — | — | US | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20230220384-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-07-13 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| EP-4153604-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2023-03-29 | — | — | EP | disclosed |
| EP-4153747-A2 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | Wave Life Sciences Ltd. (SG) | 2023-03-29 | — | — | EP | disclosed |
| EP-4022059-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | Wave Life Sciences Ltd. (SG) | 2022-07-06 | — | — | EP | disclosed |
| US-20210228615-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-07-29 | — | — | US | disclosed |
| US-20210198305-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | PFIZER INC. | 2021-07-01 | — | — | US | disclosed |
| WO-2021071858-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-04-15 | — | — | WO | disclosed |
| US-20200190515-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-06-18 | — | — | US | disclosed |
| US-20200190515-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-06-18 | — | — | US | disclosed |
| US-20200157545-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-05-21 | — | — | US | disclosed |
| US-20200157545-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-05-21 | — | — | US | disclosed |
| WO-2019075357-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240175018-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | CYP3A4 4763/4885TPSAB1 3477/4885TPSD1 3494/4885 |
| US-20200190515-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | CYP3A4 4763/4885TPSAB1 3477/4885TPSD1 3494/4885 |
| US-20210228615-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | SMN1; SMN2, RBM17, RBM22 | CYP3A4 4875/4885TPSAB1 4858/4885TPSD1 4824/4885 |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | CYP3A4 4595/4885TPSAB1 4634/4885TPSD1 4525/4885 |
| US-20200157545-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | CYP3A4 4846/4885TPSAB1 3679/4885TPSD1 4017/4885 |
| US-20210198305-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, NSUN3 | CYP3A4 4737/4885TPSAB1 4206/4885TPSD1 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.